Comparative Pharmacology
Head-to-head clinical analysis: ELLA versus FALLBACK SOLO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ELLA versus FALLBACK SOLO.
ELLA vs FALLBACK SOLO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective progesterone receptor modulator (SPRM) with antagonistic and partial agonistic activity. Delays or inhibits ovulation, alters endometrial receptivity, and impairs implantation.
FALLBACK SOLO is a small molecule inhibitor of the Hedgehog signaling pathway. It binds to and inhibits Smoothened (SMO), a transmembrane protein that activates the GLI transcription factors. This inhibition blocks the aberrant activation of the Hedgehog pathway, which is implicated in the growth of certain cancers.
30 mg orally as a single dose within 120 hours of unprotected intercourse.
100 mg orally once daily
None Documented
None Documented
Terminal half-life is approximately 24.7 hours (range 20–30 hours), allowing for single-dose emergency contraception.
Terminal half-life: 12 hours (range 10–14 h); clinical context: once-daily dosing achieves steady state in 2.5 days
Primarily fecal (≈86%) with minimal renal excretion (≈10%). Biliary elimination of metabolites is also significant.
Renal: 80% unchanged; fecal: 15% as metabolites; biliary: 5%
Category C
Category C
Emergency Contraceptive
Emergency Contraceptive